NDC 72205-0098-72: Pyridostigmine Bromide 60 mg/5mL Solution, 473 mL Bottle
This is a package of 473 mL of Pyridostigmine Bromide 60 mg/5mL Solution from Novadoz Pharmaceuticals LLC, first listed with the FDA Sep 2023 and currently FDA-listed; retail pharmacies pay about $0.7131 per mL (NADAC). It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 72205-098-72 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 72205 labeler · 098 product · 72 package
- Package marketed since
- Sep 26, 2023
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Billing quantity
- 473 mL per package
- Barcode (UPC)
- 0372205098725
- Medicaid fills, this package
- 871 prescriptions in the last four reported quarters
- FDA record last changed
- Nov 21, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 004763
- GCN: 18520
- GPI-14 (Medi-Span): 76000050102060
- HICL (First Databank): 001990
- AHFS class code: 12:04.00.00
- RxCUI (RxNorm): 903843
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Cholinesterase Inhibitor class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Pyridostigmine is used to treat myasthenia gravis. Pyridostigmine is in a class called cholinergic agents. It works by increasing the amount of certain natural substances in the body to improve nerve and muscle activity.
Read the full MedlinePlus article ↗- It depends on the product. Mestinon and other oral forms treat myasthenia gravis. Regonol injection reverses muscle relaxants after surgery. A military-only version is for soman ne...
- For myasthenia gravis products, follow your prescriber and label. The military-only extended-release tablet must be taken with a medium-fat or high-fat meal, not on an empty stomac...
- Stomach upset such as diarrhea, cramps and nausea is most common. Muscle twitching, sweating and extra saliva can also happen. Call your doctor if they bother you.
- Get help right away for trouble breathing, severe dizziness, fainting, or increasing muscle weakness. These can be signs of a serious reaction or too much medicine.
Patient education
Drug interactions
Supplement & herbal interactions
Some supplements/herbs that may interact with Pyridostigmine Bromide — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.713 | $337.30 / 473 ml |
| Medicaid paysCMS SDUD · 12 mo | $0.9104 | $430.62 / 473 ml |
| Medicare drug plans payPart D · Q2 2026 | $1.24 | $587.28 / 473 ml |
Where does this data come from?
- CMS NADAC weekly file · file of Nov 18, 2026
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 72205-0098-72 You're viewing this Main listing | 473 mL in 1 BOTTLE | 2023-09-26 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Pryidostigmine Bromide 60 mg/5mL 16571-0833-16 | Rising | 473 ml | $0.713 | AA | Availability likely | — |
| Pyridostigmine Bromide 60 mg/5mL 42192-0626-16 | Acella | 473 ml | $0.713 | AA | Availability likely | — |
| Pyridostigmine Bromide 60 mg/5mL 69238-1731-02 | Amneal | 473 ml | $0.713 | AA | Availability likely | — |
| Pyridostigmine 60 mg/5mL 70954-0148-10 | Novitium | 473 ml | $0.713 | AA | Availability likely | — |
| Pyridostigmine Bromide 60 mg/5mLthis 72205-0098-72 | Novadoz | 473 ml | $0.713 | AA | Availability likely | — |
| pyridostigmine bromide 60 mg/5mL 68682-0307-05 | Oceanside | 473 ml | $0.842 | AA | Discontinued | +18% |
| Mestinon 60 mg/5mL 00187-3012-20 | Bausch | 473 ml | — | AA | FDA listed | — |
| Pryidostigmine Bromide 60 mg/5mL 24689-0104-01 | Apnar | 473 ml | — | AA | FDA listed | — |
| Pyridostigmine Bromide 60 mg/5mL 66689-0406-10 | VistaPharm, | 10 cups | — | AA | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file · file of Nov 18, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Pyridostigmine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3K9958V90M
A liquid solvent derived from fermentation or chemical synthesis. In medicines, alcohol dissolves active ingredients, helps preserve the product, and improves how the body absorbs certain drugs.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII 33X04XA5AT
Lactic acid is a naturally occurring organic acid derived from milk or plant sources. It lowers and maintains pH in formulations, helps preserve the product, and can enhance ingredient stability and absorption.
-
UNII OJ245FE5EU
Sodium benzoate is a salt derived from benzoic acid, a preservative. It's added to medicines to prevent growth of bacteria, fungi, and other microorganisms that could spoil the product.
-
UNII 506T60A25R
Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
-
UNII C151H8M554
A natural sugar derived from sugar cane or sugar beets. It's used as a sweetener, filler, and binder to improve taste, add bulk, and help hold tablet or capsule ingredients together.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Novadoz Pharmaceuticals LLC labeler code 72205
- Doxepin Hydrochloride 100 mg Capsule NDC 72205-092-91
- Vigabatrin 50 mg/mL For Solution NDC 72205-093-50
- Levetiracetam 250 mg Tablet, Film Coated NDC 72205-094-92
- Levetiracetam 500 mg Tablet, Film Coated NDC 72205-095-92
- Levetiracetam 750 mg Tablet, Film Coated NDC 72205-096-92
- Levetiracetam 1000 mg Tablet, Film Coated NDC 72205-097-30
- sirolimus 1 mg/mL Solution NDC 72205-099-78
- Fluphenazine Decanoate 25 mg/mL Injection, Solution NDC 72205-100-01
- Bumetanide .25 mg/mL Injection NDC 72205-101-07
- Bumetanide .25 mg/mL Injection NDC 72205-102-07
- Chlorpromazine Hydrochloride 25 mg Tablet, Sugar Coated NDC 72205-104-91
- Chlorpromazine Hydrochloride 50 mg Tablet, Sugar Coated NDC 72205-105-91
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATION: Pyridostigmine bromide oral solution is useful in the treatment of myasthenia gravis.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION: Pyridostigmine Bromide Oral Solution, USP is available in following form: Oral Solution - raspberry-flavored, containing 60 mg pyridostigmine bromide per teaspoonful (5 mL). This form permits accurate dosage adjustment for children and “brittle” myasthenic patients who require fractions of 60 mg doses. It is more easily swallowed, especially in the morning, by patients with bulbar involvement.
Dosage: The size and frequency of the dosage must be adjusted to the needs of the individual patient. Oral Solution: The average dose is ten 5 mL teaspoonfuls daily, spaced to provide maximum relief when maximum strength is needed. In severe cases as many as 25 teaspoonfuls a day may be required, while in mild cases one to six teaspoonfuls a day may suffice.
NOTE: For information on a diagnostic test for myasthenia gravis, and for the evaluation and stabilization of therapy, please see product literature on Tensilon (edrophonium chloride).
⛔ Contraindications ▾
CONTRAINDICATIONS: Pyridostigmine bromide is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below.
⚠️ Warnings ▾
WARNINGS: Although failure of patients to show clinical improvement may reflect underdosage, it can also be indicative of overdosage. As is true of all cholinergic drugs, overdosage of pyridostigmine bromide may result in cholinergic crisis, a state characterized by increasing muscle weakness which, through involvement of the muscles of respiration, may lead to death. Myasthenic crisis due to an increase in the severity of the disease is also accompanied by extreme muscle weakness, and thus may be difficult to distinguish from cholinergic crisis on a symptomatic basis.
Such differentiation is extremely important, since increases in doses of pyridostigmine bromide or other drugs of this class in the presence of cholinergic crisis or of a refractory or “insensitive” state could have grave consequences. Osserman and Genkins 1 indicate that the differential diagnosis of the two types of crisis may require the use of Tensilon (edrophonium chloride) as well as clinical judgment. The treatment of the two conditions obviously differs radically.
Whereas the presence of myasthenic crisis suggests the need for more intensive anticholinesterase therapy, the diagnosis of cholinergic crisis, according to Osserman and Genkins 1 , calls for the prompt withdrawal of all drugs of this type. The immediate use of atropine in cholinergic crisis is also recommended. Atropine may also be used to abolish or obtund gastrointestinal side effects or other muscarinic reactions; but such use, by masking signs of overdosage, can lead to inadvertent induction of cholinergic crisis.
For detailed information on the management of patients with myasthenia gravis, the physician is referred to one of the excellent reviews such as those by Osserman and Genkins 2 , Grob 3 or Schwab. 4,5 Usage in Pregnancy: The safety of pyridostigmine bromide during pregnancy or lactation in humans has not been established. Therefore, use of pyridostigmine bromide in women who may become pregnant requires weighing the drug’s potential benefits against its possible hazards to mother and child.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS: The side effects of pyridostigmine bromide are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis and diaphoresis. Nicotinic side effects are comprised chiefly of muscle cramps, fasciculation and weakness.
Muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. As with any compound containing the bromide radical, a skin rash may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication.
To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY: Pyridostigmine bromide inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine (Prostigmin), but differs from it in certain clinically significant respects; for example, pyridostigmine is characterized by a longer duration of action and fewer gastrointestinal side effects.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED: Pyridostigmine Bromide Oral Solution USP, 60 mg pyridostigmine bromide per teaspoonful (5 mL) is available as a clear, raspberry flavored solution and 0.23% w/w alcohol. It is supplied as follows: Bottles of 16 fluid ounces, (1 pint, 473 mL) NDC 72205-098-72 Store at 25°C (77°F); excursions permitted to 15° to 30°C (59°to 86°F). [see USP Controlled Room Temperature]. Dispense in tight, light-resistant containers as defined by the USP.
📋 Description ▾
DESCRIPTION: Pyridostigmine bromide oral solution, USP is an orally active cholinesterase inhibitor. Chemically, pyridostigmine bromide, USP is 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate. Its structural formula is: The molecular formula of pyridostigmine bromide, USP is C 9 H 13 BrN 2 O 2 having a molecular weight of 261.12.
Pyridostigmine bromide oral solution, USP contains 60 mg pyridostigmine bromide per teaspoonful in a vehicle containing 0.23% w/w alcohol, glycerin, lactic acid, sodium benzoate, sorbitol, sucrose, raspberry-flavor (propylene glycol, Nat & Art flavor) and water. pyridostigmine-structure
⚠️ Precautions ▾
PRECAUTION: Pyridostigmine is mainly excreted unchanged by the kidney. 6,7,8 Therefore, lower doses may be required in patients with renal disease, and treatment should be based on titration of drug dosage to effect. 6,7 Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
📚 References ▾
REFERENCES: 1. Osserman KE, Genkins G. Studies in myasthenia gravis: Reduction in mortality rate after crisis.
JAMA. Jan 1963; 183:97-101. 2.
Osserman KE, Genkins G. Studies in myasthenia gravis. NY State J Med.
June 1961; 61:2076-2085. 3. Grob D.
Myasthenia gravis. A review of pathogenesis and treatment. Arch Intern Med.
Oct 1961; 108:615-638. 4. Schwab RS.
Management of myasthenia gravis. New Eng J Med. Mar 1963; 268:596-597.
5. Schwab RS. Management of myasthenia gravis.
New Eng J Med. Mar 1963; 268:717-719. 6.
Cronnelly R, Stanski DR, Miller RD, Sheiner LB. Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther.
1980; 28: No. 1, 78-81. 7.
Miller RD. Pharmacodynamics and pharmacokinetics of anticholinesterase. In: Ruegheimer E, Zindler M, ed.
Anesthesiology. (Hamburg, Germany: Congress; Sep 14-21, 1980; 222-223.) (Int Congr. No.
538), Amsterdam, Netherlands: Excerpta Medica; 1981. 8. Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F.
Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther. 1985; 5:495-501.
The brands listed are trademarks or registered trademarks of their respective owners and are not affiliated with and do not endorse Novadoz Pharmaceuticals LLC. Manufactured by: MSN Pharmaceuticals Inc. Piscataway, NJ 08854 Distributed by: Novadoz Pharmaceuticals LLC Piscataway, NJ 08854 -3714 Issued on: 09/2023
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL PRINCIPAL DISPLAY PANEL 1 Pint (473 mL) Bottle Label pyridostigmine-bottle-label